- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 4/11/24: 1/3 of Americans Have Skipped Healthcare Visit Due to Inability to Pay, MedQuest Names New CCIO & more
The latest news for pharma industry insiders.
How Efficient Logistics Can Change the Lives of Rare Disease Patients
If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
More than a Third of Americans Have Skipped a Healthcare Visit Due to Inability to Pay
The average American can afford a maximum of a $97 for out-of-pocket healthcare expenses.
In Battle Over Health Care Costs, Private Equity Plays Both Sides
As medical practices owned by private equity firms fuel overbilling, a payment tool also backed by such investors helps insurers boost their profits.
MedQuest Names Aalpen Patel Chief Clinical and Innovation Officer
MedQuest Associates (MedQuest), has selected Dr. Aalpen Patel as Chief Clinical and Innovation Officer. Dr. Patel joined on March 18 in a new role overseeing all functions related to clinical practices and innovation in product development and care delivery. He reports to CEO Jason Howard and serves on the company’s Executive Leadership Council.
Brigitte Mittwich on LinkedIn:
Conversations like Marie Teil’s on the Pharmaceutical Executive podcast are crucial in shedding light on the data gap faced by women of childbearing age and opportunities for change. Listen below!
https://lnkd.in/e2Q_sMbj
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
